• <kbd id="sdring" ><rt id="sdring" ><bdo id="sdring" ></bdo></rt></kbd>
  • <source id="sdring" ></source>

    <b id="sdring" ></b>
  • <b id="sdring" ><acronym id="sdring" ><meter id="sdring" ></meter></acronym></b>

        <del id="sdring" ></del>
        Log in
        Forgot password ?
        Become a member for free
        Sign up
        Sign up
        New member
        Sign up for FREE
        New customer
        Discover our services
        Dynamic quotes 

        MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Alligator Bioscience AB (publ)    ATORX   SE0000767188


        News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

        Alligator Bioscience publ : Nomination committee appointed for the 2020 Annual General Meeting of Alligator Bioscience AB

        share with twitter share with LinkedIn share with facebook
        share via e-mail
        11/14/2019 | 08:11am EST

        Lund - Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that the Nomination Committee for the Annual General Meeting on May 5, 2020 has been appointed.

        According to the instructions for the Nomination Committee adopted at the Annual General Meeting on May 9, 2019, the Nomination Committee for Alligator Bioscience's Annual General Meeting 2020 shall consist of four members, representing the three largest shareholders as of the last weekday in June, together with the Chairman of the Board. If the shareholder does not exercise his right to appoint a member of the nomination committee, the next largest shareholder shall be entitled to appoint a member of the nomination committee to the number of votes.

        Based on the above, the Nomination Committee for the Annual General Meeting 2020 has been determined to consist of the following persons, who together represent approximately 20 percent of the number of shares and votes in the company as of the end of October 2019: Hans-Peter Ostler, representing Jonas Sjogren; Jan Lundstrom, representing Sunstone Life Science Ventures II K / S; Lars Bergkvist, representing Lars Spanberg and Peter Benson, Chairman of the Board.

        Lars Bergkvist has been appointed Chairman of the Nomination Committee.

        The Nomination Committee's task is to prepare and present proposals for the Chairman of the Annual General Meeting, the number of Board members elected by the Annual General Meeting, the Chairman and other members elected by the Board of Directors, fees and other remuneration to each of the Board members elected by the AGM and to the members of the Board of Auditors, , fees to the auditor as well as the election of the nomination committee or a decision on principles for appointing the nomination committee and decisions on instructions for the nomination committee.

        Shareholders who wish to submit comments or submit proposals to the Nomination Committee may do so via email marked 'Att. Nominating Committee 'to or via letter to Alligator Bioscience AB, Nominating Committee, Medicon Village, 223 81 Lund. In order for the Nomination Committee to consider a proposal, the proposal must have been submitted well in advance of the AGM, but no later than 31 January 2020.

        The nomination committee's proposals will be presented in the notice of the AGM and on the company's website.


        Cecilia Hofvander

        Tel: 046-540 82 06


        The information was made available for publication on November 13, 2019, at the time of the above contact person. 10.30.

        About Alligator Bioscience

        Alligator Bioscience is a public Swedish biotechnology company that develops tumor-directed cancer immunotherapy. Alligator's project portfolio includes six drug candidates in clinical and preclinical development phase: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (in co-development with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development) by Shanghai Henlius Inc.). Alligator's shares are traded on Nasdaq Stockholm under the ticker 'ATORX'. The company was founded in 2001 and today has about 55 employees. The head office is located at Medicon Village in Lund, Sweden.

        (C) 2019 Electronic News Publishing, source ENP Newswire

        share with twitter share with LinkedIn share with facebook
        share via e-mail
        Latest news on ALLIGATOR BIOSCIENCE AB (P
        11/14ALLIGATOR BIOSCIENCE PUBL : Nomination committee appointed for the 2020 Annual G..
        11/13ALLIGATOR BIOSCIENCE PUBL : Nomination Committee appointed in respect of AGM 202..
        11/11APTEVO THERAPEUTICS : and Alligator Bioscience present new preclinical data for ..
        11/08ALLIGATOR BIOSCIENCE PUBL : Aptevo Therapeutics and?Alligator Bioscience present..
        11/06ALLIGATOR BIOSCIENCE : ?ATOR-1017 Induces Long-Lasting Immunity – New Prec..
        11/06ALLIGATOR BIOSCIENCE : ?ATOR-1017 Induces Long-Lasting Immunity - New Preclinica..
        10/24ALLIGATOR BIOSCIENCE AB : Interim report January-September 2019
        08/21ALLIGATOR BIOSCIENCE : signs antibody agreement with Biotheus Inc. in China
        08/20ALLIGATOR BIOSCIENCE : signs antibody agreement for Greater China with Biotheus ..
        07/31ALLIGATOR BIOSCIENCE : regains global rights from Janssen to CD40 agonistic anti..
        More news
        Financials (SEK)
        Sales 2019 3,12 M
        EBIT 2019 -207 M
        Net income 2019 -203 M
        Finance 2019 224 M
        Yield 2019 -
        P/E ratio 2019 -4,86x
        P/E ratio 2020 -4,28x
        EV / Sales2019 244x
        EV / Sales2020 27,5x
        Capitalization 985 M
        Duration : Period :
        Alligator Bioscience AB (publ) Technical Analysis Chart | MarketScreener
        Full-screen chart
        Technical analysis trends ALLIGATOR BIOSCIENCE AB (P
        Short TermMid-TermLong Term
        Income Statement Evolution
        Mean consensus OUTPERFORM
        Number of Analysts 4
        Average target price 22,25  SEK
        Last Close Price 13,80  SEK
        Spread / Highest target 73,9%
        Spread / Average Target 61,2%
        Spread / Lowest Target 52,2%
        EPS Revisions
        Per Norl駭 Chief Executive Officer
        Peter James Arthur Benson Chairman
        Per-Olof Schrewelius Chief Financial Officer
        Charlotte A. Russell Chief Medical Officer
        Kenth Ingemar Petersson Independent Director
        Sector and Competitors
        1st jan.Capitalization (M$)
        IQVIA HOLDINGS INC.25.42%28 271
        LONZA GROUP33.49%25 571
        CELLTRION, INC.--.--%20 341
        SEATTLE GENETICS, INC.99.95%19 416
        INCYTE CORPORATION37.49%18 479